ClinicalTrials.Veeva

Menu

Identification of Mutations Responsible for Rare Familial Skin Diseases by Next Generation Sequencing (DERMA-SEQ)

U

University Hospital, Strasbourg, France

Status

Unknown

Conditions

Very Rare Dermatologic Diseases
Familial Lipomatosis

Study type

Observational

Funder types

Other

Identifiers

NCT02509650
6024 (Other Identifier)

Details and patient eligibility

About

The primary purpose of the protocol is to use next generation sequencing to identify pathogenic variants in genes involved in very rare skin diseases.

The secondary purpose will be to study the genotype-phenotype correlation in order to re-evaluate the classification of these disorders. This work could help in the understanding of the physiopathology of very rare skin disorders.

Enrollment

25 estimated patients

Sex

All

Ages

2+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • patients affected by familial lipomatosis
  • patients with rare dermatologic disease without molecular diagnosis
  • written informed consent is obtained from the patient and his/her family

Exclusion criteria

  • the patient does not want to participate to the protocol
  • the patient is already included in another study using next generation sequencing technologies

Trial contacts and locations

2

Loading...

Central trial contact

Salima EL CHEHADEH, MD; Dan LIPSKER, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems